Lysosomal storage diseases - The horizon expands

Nature Reviews Neurology

Volumn 9, Issue 10, 2013, Pages 583-598

  Boustany, Rose Mary Naaman ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; COMPLEMENTARY DNA; CYSTAFOS; ELIGLUSTAT; FLUPIRTINE; GLUCAN 1,4 ALPHA GLUCOSIDASE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; METHOTREXATE; METHYL BETA CYCLODEXTRIN; MIGALASTAT; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB;

APOPTOSIS; ARTICLE; AUTOPHAGY; BIOLOGICAL THERAPY; BIOTECHNOLOGICAL PROCEDURES; BLOOD BRAIN BARRIER; BONE MARROW TRANSPLANTATION; CALCIUM BALANCE; CELL ACTIVATION; CLINICAL FEATURE; DISEASE ASSOCIATION; ENDOPLASMIC RETICULUM; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GLOBOID CELL LEUKODYSTROPHY; GLYCOGEN STORAGE DISEASE TYPE 2; HEALTH CARE COST; HUMAN; HURLER SYNDROME; LIPID ANALYSIS; LYSOSOME STORAGE DISEASE; METACHROMATIC LEUKODYSTROPHY; MOLECULAR DYNAMICS; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN UNFOLDING; SANFILIPPO SYNDROME; SIGNAL TRANSDUCTION; STOP CODON READTHROUGH TECHNOLOGY; SUBSTRATE REDUCTION THERAPY; SYNDROME DELINEATION; VIRAL GENE DELIVERY SYSTEM;

HUMANS; LYSOSOMAL STORAGE DISEASES; NEURONAL CEROID-LIPOFUSCINOSES;

EID: 84885679000     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2013.163     Document Type: Article

References (195)

1. De Duve, C. The lysosome turns fifty. Nat. Cell Biol. 7, 847-849 (2005).
2. Hers, H. G. Inborn lysosomal diseases. Gastroenterology 48, 625-633 (1965).
3. Sachs, B. A family form of idiocy, generally fatal and associated with early blindness (amaurotic family idiocy). N. Y. Med. J. 63, 697-703 (1896).
4. Boustany R. M. & Mousallem, T. in Emery and Rimoin?s Principles and Practice of Medical Genetics (eds Rimoin, D. et al.) 2449-2485 (Elsevier, 2007).
5. Ciechanover, A. Intracellular protein degradation: From a vague idea, through the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Biochim. Biophys. Acta 1824, 3-13 (2012).
6. Platt, F. M. & Lachmann, R. H. Treating lysosomal storage disorders: Current practice and future prospects. Biochim. Biophys. Acta 1793, 737-745 (2009).
7. Ballabio, A. & Gieselmann, V. Lysosomal disorders: From storage to cellular damage. Biochim. Biophys. Acta 1793, 684-696 (2009).
8. Deduve, C. From cytases to lysosomes. Fed. Proc. 23, 1045-1049 (1964).
9. Desnick, R. J. & Schuchman, E. H. Enzyme replacement therapy for lysosomal diseases: Lessons from 20 years of experience and remaining challenges. Annu. Rev. Genomics Hum. Genet. 13, 307-335 (2012).
10. Huizing, M., Helip-Wooley, A., Westbroek, W., Gunay-Aygun, M. & Gahl, W. A. Disorders of lysosome-related organelle biogenesis: Clinical and molecular genetics. Annu. Rev. Genomics Hum. Genet. 9, 359-386 (2008).
11. Berkovic, S. F. et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am. J. Hum. Genet. 82, 673-684 (2008).
12. Vogt, H. Uber familiare amaurotische idiotie und verwandte krankheitsbilder [German]. Monatsschr. Psychiatr. Neurol. 19, 161-171 (1905).
13. Vitner, E. B., Platt, F. M. & Futerman, A. H. Common and uncommon pathogenic cascades in lysosomal storage diseases. J. Biol. Chem. 285, 20423-20427 (2010).
14. Aula, P. et al. ?Salla disease?: A new lysosomal storage disorder. Arch. Neurol. 36, 88-94 (1979).
15. Arvio, M., Autio, S. & Louhiala, P. Early clinical symptoms and incidence of aspartylglucosaminuria in Finland. Acta Paediatr. 82, 587-589 (1993).
16. Frustaci, A. et al. Improvement in cardiac function in the cardiac variant of Fabry?s disease with galactose-infusion therapy. N. Engl. J. Med. 345, 25-32 (2001).
17. Kumperscak, H. G., Paschke, E., Gradisnik, P., Vidmar, J. & Bradac, S. U. Adult metachromatic leukodystrophy: Disorganized schizophrenia-like symptoms and postpartum depression in 2 sisters. J. Psychiatry Neurosci. 30, 33-36 (2005).
18. Arsov, T. et al. Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6. Am. J. Hum. Genet. 88, 566-573 (2011).
19. Stengel, O. C. Beretning om et mærkeligt Sygdomstilfaelde hos fire Sødskende I Nærheden af Röraas [Norwegian]. Eyr. Med. Tidskr. 1, 347-352 (1826).
20. Boustany, R. M., Alroy, J. & Kolodny, E. H. Clinical classification of neuronal ceroid-lipofuscinosis subtypes. Am. J. Med. Genet. SUPPL. 5, 47-58 (1988).
21. Goebel, H. H., Gerhard, L., Kominami, E. & Haltia, M. Neuronal ceroid-lipofuscinosis-late-infantile or Jansky-Bielschowsky type-revisited. Brain Pathol. 6, 225-228 (1996).
22. Batten, F. E. Cerebral degeneration with symmetrical changes in the maculae in two members of family. Trans. Ophthalmol. Soc. UK 23, 386-390 (1903).
23. Vogt, H. Familiare amaurotische idiotie. Histologische and histopathologische studien [German]. Arch. Kinderheilk. 51, 1-35 (1909).
24. Jansky, J. Sur un cas jusqu?a présente non décrit De l?idiotie amaurotique familiale compliquée par une hypolasie du cervelet [French]. Sborn. Lek. 13, 165-196 (1908).
25. Bielschowsky, M. Uber spatinfantile amaurotische Idiotie mit Kleinhirnsymptomen [German]. Dtsch. Z. Nervenheilk. 50, 7-29 (1913).
26. Jardim, L. B., Villanueva, M. M., De Souza, C. F. & Netto, C. B. Clinical aspects of neuropathic lysosomal storage disorders. J. Inherit. Metab. Dis. 33, 315-329 (2010).
27. Klenk, E. Beitrage zur Chemie der Lipidosen, Niemann-Picksche und amaurotische Idiotie, Hoppe-Seyler [German]. Z. Physiol. Chem. 262, 128-143 (1939).
28. Svennerholm, L. The chemical structure of normal human brain and Tay-Sachs gangliosides. Biochem. Biophys. Res. Commun. 9, 436-441 (1962). 29.
29. Isolation of a novel gene underlying Batten disease, CLN3. The International Batten Disease Consortium. Cell 82, 949-957 (1995).
30. Lane, S. C., Jolly, R. D., Schmechel, D. E., Alroy, J. & Boustany, R. M. Apoptosis as the mechanism of neurodegeneration in Batten?s disease. J. Neurochem. 67, 677-683 (1996).
31. Haltia, M. & Goebel, H. H. The neuronal ceroid-lipofuscinoses: A historical introduction. Biochim. Biophys. Acta http://dx.doi.org/10.1016/j. bbadis.2012.08.012.
32. Haddad, S. E. et al. CLN5 and CLN8 protein association with ceramide synthase: Biochemical and proteomic approaches. Electrophoresis 33, 3798-3809 (2012).
33. Mole, S., Williams, R. & Goebel, H. (Eds) The Neuronal Ceroid Lipofuscinoses, Batten Disease (Oxford University Press, 2012).
34. Saftig, P., Beertsen, W. & Eskelinen, E. L. LAMP-2: A control step for phagosome and autophagosome maturation. Autophagy 4, 510-512 (2008).
35. Weaver, T. E., Na, C. L. & Stahlman, M. Biogenesis of lamellar bodies, lysosome-related organelles involved in storage and secretion of pulmonary surfactant. Semin. Cell Dev. Biol. 13, 263-270 (2002).
36. Saftig, P. & Klumperman, J. Lysosome biogenesis and lysosomal membrane proteins: Trafficking meets function. Nat. Rev. Mol. Cell Biol. 10, 623-635 (2009).
37. Schultz, M. L., Tecedor, L., Chang, M. & Davidson, B. L. Clarifying lysosomal storage diseases. Trends Neurosci. 34, 401-410 (2011).
38. Braunlin, E. A. et al. Cardiac disease in patients with mucopolysaccharidosis: Presentation, diagnosis and management. J. Inherit. Metab. Dis. 34, 1183-1197 (2011).
39. Kwon, J. Y. et al. High prevalence of carpal tunnel syndrome in children with mucopolysaccharidosis type II (Hunter syndrome). Am. J. Med. Genet. A 155A, 1329-1335 (2011).
40. Jurecka, A., Opoka-Winiarska, V., Jurkiewicz, E., Marucha, J. & Tylki-Szymańska, A. Spinal cord compression in Maroteaux-Lamy syndrome: Case report and review of the literature with effects of enzyme replacement therapy. Pediatr. Neurosurg. 48, 191-198 (2012).
41. Pastores, G. M. et al. The MPS I registry: Design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol. Genet. Metab. 91, 37-47 (2007).
42. Guillemot, N., Troadec, C., De Villemeur, T. B., Clément, A. & Fauroux, B. Lung disease in niemann-Pick disease. Pediatr. Pulmonol. 42, 1207-1214 (2007).
43. Muhlebach, M. S., Wooten, W. & Muenzer, J. Respiratory manifestations in mucopolysaccharidoses. Paediatr. Respir. Rev. 12, 133-138 (2011).
44. Muenzer, J. Overview of the mucopolysaccharidoses. Rheumatology (Oxford) 50 (SUPPL. 5), v4-v12 (2011).
45. Brama, I., Gay, I., Feinmesser, R. & Springer, C. Upper airway obstruction in Hunter syndrome. Int. J. Pediatr. Otorhinolaryngol. 11, 229-235 (1986).
46. Shih, S. L., Lee, Y. J., Lin, S. P., Sheu, C. Y. & Blickman, J. G. Airway changes in children with mucopolysaccharidoses. Acta Radiol. 43, 40-43 (2002).
47. Shapiro, J., Strome, M. & Crocker, A. C. Airway obstruction and sleep apnea in Hurler and Hunter syndromes. Ann. Otol. Rhinol. Laryngol. 94, 458-461 (1985).
48. Morehead, J. M. & Parsons, D. S. Tracheobronchomalacia in Hunter?s syndrome. Int. J. Pediatr. Otorhinolaryngol. 26, 255-261 (1993).
49. Bonten, E. J. et al. Targeting macrophages with baculovirus-produced lysosomal enzymes: Implications for enzyme replacement therapy of the glycoprotein storage disorder galactosialidosis. FASEB J. 18, 971-973 (2004).
50. Thappa, D. M., Singh, A., Jaisankar, T. J., Rao, R. & Ratnakar, C. Pebbling of the skin: A marker of Hunter?s syndrome. Pediatr. Dermatol. 15, 370-373 (1998).
51. Möhrenschlager, M., Lauenstein, M., Ring, J. & Steiner, C. Synophrys. Eur. J. Med. Genet. 53, 225-226 (2010).
52. Spranger, J. in Emery and Rimoin?s Principles and Practice of Medical Genetics (eds Rimion, D. L. et al.) 2403-2412 (Elsevier, 2007).
53. Eng, C. M. et al. Fabry disease: Baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis. 30, 184-192 (2007).
54. Collins, R. C., Dobkin, B. H. & Choi, D. W. Selective vulnerability of the brain: New insights into the pathophysiology of stroke. Ann. Intern. Med. 110, 992-1000 (1989).
55. Huebner, E. A. & Strittmatter, S. M. Axon regeneration in the peripheral and central nervous systems. Results Probl. Cell Differ. 48, 339-351 (2009).
56. Hoffmann, B. & Mayatepek, E. Neurological manifestations in lysosomal storage disorders-from pathology to first therapeutic possibilities. Neuropediatrics 36, 285-289 (2005).
57. Walkley, S. U. Pathogenic cascades in lysosomal disease-why so complex? J. Inherit. Metab. Dis. 32, 181-189 (2009).
58. Suvarna, J. C. & Hajela, S. A. Cherry-red spot. J. Postgrad. Med. 54, 54-57 (2008).
59. Birch, D. G. Retinal degeneration in retinitis pigmentosa and neuronal ceroid lipofuscinosis: An overview. Mol. Genet. Metab. 66, 356-366 (1999).
60. Lang, G. E. & Maumenee, I. H. in Retinal Dystrophies and Degenerations (ed. Newsome, D. A.) 319-340 (Raven Press, 1988).
61. Debs, R. et al. Krabbe disease in adults: Phenotypic and genotypic update from a series of 11 cases and a review. J. Inherit. Metab. Dis. http://dx.doi.org/10.1007/s10545-012-9560-4.
62. Siddiqi, Z. A., Sanders, D. B. & Massey, J. M. Peripheral neuropathy in Krabbe disease: Effect of hematopoietic stem cell transplantation. Neurology 67, 268-272 (2006).
63. Escolar, M. L. et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe?s disease. N. Engl. J. Med. 352, 2069-2081 (2005).
64. Kolodny, E. & Moser, H. W. in The Metabolic Basis of Inherited Disease (eds Stanbury, J. B. et al.) 881-905 (Mc-Graw-Hill, 1983).
65. Biegstraaten, M. et al. Small fiber neuropathy in Fabry disease. Mol. Genet. Metab. 106, 135-141 (2012).
66. Hannun, Y. A. & Bell, R. M. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 243, 500-507 (1989).
67. Al Sawaf, S., Mayatepek, E. & Hoffmann, B. Neurological findings in Hunter disease: Pathology and possible therapeutic effects reviewed. J. Inherit. Metab. Dis. 31, 473-480 (2008).
68. Tuttolomondo, A. et al. Neurological complications of Anderson-Fabry disease. Curr. Pharm. Des. [Epub ahead of print].
69. Neto, Â. R., Holanda, G. B., Farias, M. C., Santos Da Costa, G. & Pereira, H. S. Hydrocephalus in mucopolysaccharidosis type VI successfully treated with endoscopic third ventriculostomy. J. Neurosurg. Pediatr. 11, 327-330 (2013).
70. Gupta, N., Rath, G. P., Bala, R., Reddy, B. K. & Chaturvedi, A. Anesthetic management in children with Hurler?s syndrome undergoing emergency ventriculoperitoneal shunt surgery. Saudi J. Anaesth. 6, 178-180 (2012).
71. Manara, R. et al. Brain and spine MRI features of Hunter disease: Frequency, natural evolution and response to therapy. J. Inherit. Metab. Dis. 34, 763-780 (2011).
72. Aliabadi, H. et al. Clinical outcome of cerebrospinal fluid shunting for communicating hydrocephalus in mucopolysaccharidoses I, II, and III: A retrospective analysis of 13 patients. Neurosurgery 67, 1476-1481 (2010).
73. Palmucci, S. et al. Imaging findings of mucopolysaccharidoses: A pictorial review. Insights Imaging http://dx.doi.org/10.1007/s13244-013-0246-8.
74. Jeyakumar, M., Dwek, R. A., Butters, T. D. & Platt, F. M. Storage solutions: Treating lysosomal disorders of the brain. Nat. Rev. Neurosci. 6, 713-725 (2005).
75. Garbutt, S. & Harris, C. M. Abnormal vertical optokinetic nystagmus in infants and children. Br. J. Ophthalmol. 84, 451-455 (2000).
76. Sunwoo, M. K., Kim, S. M., Lee, S. & Lee, P. H. Parkinsonism associated with glucocerebrosidase mutation. J. Clin. Neurol. 7, 99-101 (2011).
77. Sarpong, A. et al. Protracted course of juvenile ceroid lipofuscinosis associated with a novel CLN3 mutation (p.Y199X). Clin. Genet. 76, 38-45 (2009).
78. Lloyd-Evans, E. et al. Glucosylceramide and glucosylsphingosine modulate calcium mobilization from brain microsomes via different mechanisms. J. Biol. Chem. 278, 23594-23599 (2003).
79. Tokushige, S. et al. Isolated pyramidal tract impairment in the central nervous system of adult-onset Krabbe disease with novel mutations in the GALC gene. Brain Dev. 35, 579-581 (2013).
80. Sehgal, R., Sharma, S., Sankhyan, N., Kumar, A. & Gulati, S. Selective corticospinal tract involvement in late-onset Krabbe disease. Neurology 77, e20 (2011).
81. Kamate, M. & Hattiholi, V. Predominant corticospinal tract involvement in early-onset Krabbe disease. Pediatr. Neurol. 44, 155-156 (2011).
82. Simonaro, C. M. et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc. Natl Acad. Sci. USA 107, 222-227 (2010).
83. Suzuki, M. et al. Endosomal accumulation of Toll-like receptor 4 causes constitutive secretion of cytokines and activation of signal transducers and activators of transcription in niemann-Pick disease type C (NPC) fibroblasts: A potential basis for glial cell activation in the NPC brain. J. Neurosci. 27, 1879-1891 (2007).
84. Husebye, H. et al. Endocytic pathways regulate Toll-like receptor 4 signaling and link innate and adaptive immunity. EMBO J. 25, 683-692 (2006).
85. Johnson, G. B., Brunn, G. J., Kodaira, Y. & Platt, J. L. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor J. Immunol. 168, 5233-5239 (2002).
86. Pan, C. et al. Functional abnormalities of heparan sulfate in mucopolysaccharidosis-I are associated with defective biologic activity of FGF-2 on human multipotent progenitor cells. Blood 106, 1956-1964 (2005).
87. Puranam, K. L., Guo, W. X., Qian, W. H., Nikbakht, K. & Boustany, R. M. CLN3 defines a novel antiapoptotic pathway operative in neurodegeneration and mediated by ceramide. Mol. Genet. Metab. 66, 294-308 (1999).
88. Persaud-Sawin, D. A., VanDongen, A. & Boustany, R. M. Motifs within the CLN3 protein: Modulation of cell growth rates and apoptosis. Hum. Mol. Genet. 11, 2129-2142 (2002).
89. Persaud-Sawin, D. A. et al. Neuronal ceroid lipofuscinosis: A common pathway? Pediatr. Res. 61, 146-152 (2007).
90. Futerman, A. H. & van Meer, G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5, 554-565 (2004).
91. Domon, M. M., Besson, F., Bandorowicz-Pikula, J. & Pikula, S. Annexin A6 is recruited into lipid rafts of niemann-Pick type C disease fibroblasts in a Ca2+-dependent manner. Biochem. Biophys. Res. Commun. 405, 192-196 (2011).
92. Vainio, S. et al. Defective insulin receptor activation and altered lipid rafts in niemann-Pick type C disease hepatocytes. Biochem. J. 391, 465-472 (2005).
93. te Vruchte, D. et al. Accumulation of glycosphingolipids in niemann-Pick C disease disrupts endosomal transport. J. Biol. Chem. 279, 26167-26175 (2004).
94. Chen, C. S., Patterson, M. C., Wheatley, C. L., O?Brien, J. F. & Pagano, R. E. Broad screening test for sphingolipid-storage diseases. Lancet 354, 901-905 (1999).
95. Rusyn, E., Mousallem, T., Persaud-Sawin, D. A., Miller, S. & Boustany, R. M. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content. Pediatr. Res. 63, 625-631 (2008).
96. Persaud-Sawin, D. A. & Boustany, R. M. Cell death pathways in juvenile Batten disease. Apoptosis 10, 973-985 (2005).
97. Harati, H., Haliw, L., Cotman, S. & Boustany, R. M. Galactosylceramide (GalCer) as a potential treatment for juvenile neuronal ceroid lipofuscinosis (JNCL) in 13th International Conference on Neuronal Ceroid Lipofuscinosis (Batten Disease) & Patient Organisation Meeting. 54 (London, 2012).
98. Kobayashi, T., Shinoda, H., Goto, I., Yamanaka, T. & Suzuki, Y. Globoid cell leukodystrophy is a generalized galactosylsphingosine (psychosine) storage disease. Biochem. Biophys. Res. Commun. 144, 41-46 (1987).
99. Kanazawa, T. et al. Inhibition of cytokinesis by a lipid metabolite, psychosine. J. Cell Biol. 149, 943-950 (2000).
100. Giri, S., Khan, M., Rattan, R., Singh, I. & Singh, A. K. Krabbe disease: Psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death. J. Lipid Res. 47, 1478-1492 (2006).
101. Zaka, M. & Wenger, D. A. Psychosine-induced apoptosis in a mouse oligodendrocyte progenitor cell line is mediated by caspase activation. Neurosci. Lett. 358, 205-209 (2004).
102. Nilsson, O., Månsson, J. E., Håkansson, G. & Svennerholm, L. The occurrence of psychosine and other glycolipids in spleen and liver from the three major types of Gaucher?s disease. Biochim. Biophys. Acta 712, 453-463 (1982).
103. Kobayashi, T. et al. Accumulation of lysosphingolipids in tissues from patients with GM1 and GM2 gangliosidoses. J. Neurochem. 59, 1452-1458 (1992).
104. Aerts, J. M. et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl Acad. Sci. USA 105, 2812-2817 (2008).
105. Kolodny, E. H. & Boustany, R. M. in Hematology of Infancy and Childhood (ed. Nathan, D. O.) 1212-1247 (W. B. Saunders, 1987).
106. d?Azzo, A., Kolodny, E., Bonten, E. & Annunziata, I. in Nathan and Oski?s Hematology of Infancy and Childhood (eds Orkin, S. et al.) 1301-1422 (W. B. Saunders, Philadelphia, 2009).
107. Czeh, M., Gressens, P. & Kaindl, A. M. The yin and yang of microglia. Dev. Neurosci. 33, 199-209 (2011).
108. DiRosario, J. et al. Innate and adaptive immune activation in the brain of MPS IIIB mouse model. J. Neurosci. Res. 87, 978-990 (2009).
109. Seehafer, S. S. et al. Immunosuppression alters disease severity in juvenile Batten disease mice. J. Neuroimmunol. 230, 169-172 (2011).
110. Pelled, D. et al. Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol. Dis. 18, 83-88 (2005).
111. Korkotian, E. et al. Elevation of intracellular glucosylceramide levels results in an increase in endoplasmic reticulum density and in functional calcium stores in cultured neurons. J. Biol. Chem. 274, 21673-21678 (1999).
112. Ginzburg, L., Li, S. C., Li, Y. T. & Futerman, A. H. An exposed carboxyl group on sialic acid is essential for gangliosides to inhibit calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase: Relevance to gangliosidoses. J. Neurochem. 104, 140-146 (2008).
113. Pelled, D. et al. Inhibition of calcium uptake via the sarco/endoplasmic reticulum Ca2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J. Biol. Chem. 278, 29496-29501 (2003).
114. Ginzburg, L. & Futerman, A. H. Defective calcium homeostasis in the cerebellum in a mouse model of niemann-Pick A disease. J. Neurochem. 95, 1619-1628 (2005).
115. Tessitore, A. et al. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell 15, 753-766 (2004).
116. Kim, S. J., Zhang, Z., Hitomi, E., Lee, Y. C. & Mukherjee, A. B. Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL. Hum. Mol. Genet. 15, 1826-1834 (2006).
117. Puranam, K. et al. Upregulation of Bcl-2 and elevation of ceramide in Batten disease. Neuropediatrics 28, 37-41 (1997).
118. Kim, S. J., Zhang, Z., Lee, Y. C. & Mukherjee, A. B. Palmitoyl-protein thioesterase-1 deficiency leads to the activation of caspase-9 and contributes to rapid neurodegeneration in INCL. Hum. Mol. Genet. 15, 1580-1586 (2006).
119. Dhar, S. et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3-and CLN2-deficient neurons. Ann. Neurol. 51, 448-466 (2002).
120. Zheng, Z. et al. Downregulated adaptor protein p66Shc mitigates autophagy process by low nutrient and enhances apoptotic resistance in human lung adenocarcinoma A549 cells. FEBS J. http://dx.doi.org/10.1111/febs.12416.
121. B?chir, W. et al. The eIF2?/ATF4 pathway is essential for stress-induced autophagy gene expression. Nucleic Acids Res. http://dx.doi.org/10.1093/nar/ gkt563.
122. Su, M., Mei, Y. & Sinha, S. Role of the crosstalk between autophagy and apoptosis in cancer. J. Oncol. 2013, 102735 (2013).
123. Müller, S., Dennemärker, J. & Reinheckel, T. Specific functions of lysosomal proteases in endocytic and autophagic pathways. Biochim. Biophys. Acta 1824, 34-43 (2012).
124. Maiuri, M. C., Zalckvar, E., Kimchi, A. & Kroemer, G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 8, 741-752 (2007).
125. Raben, N., Roberts, A. & Plotz, P. H. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 26, 45-48 (2007).
126. Alvarez, V. E., Niemirowicz, G. T. & Cazzulo, J. J. The peptidases of Trypanosoma cruzi: Digestive enzymes, virulence factors, and mediators of autophagy and programmed cell death. Biochim. Biophys. Acta 1824, 195-206 (2012).
127. Pacheco, C. D. & Lieberman, A. P. Lipid trafficking defects increase Beclin-1 and activate autophagy in niemann-Pick type C disease. Autophagy 3, 487-489 (2007).
128. Chang, J. W., Choi, H., Cotman, S. L. & Jung, Y. K. Lithium rescues the impaired autophagy process in CbCln3ex7/8/ex7/8 cerebellar cells and reduces neuronal vulnerability to cell death via IMPase inhibition. J. Neurochem. 116, 659-668 (2011).
129. Settembre, C., Fraldi, A., Rubinsztein, D. C. & Ballabio, A. Lysosomal storage diseases as disorders of autophagy. Autophagy 4, 113-114 (2008).
130. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01372228?term=NCT01372228&rank=1 (2013).
131. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01757184?term=NCT01757184&rank=1 (2013).
132. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01697319?term=NCT01697319&rank=1 (2013).
133. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00668564?term=NCT00668564&rank=1 (2012).
134. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01299727?term=NCT01299727&rank=1 (2012).
135. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00638547?term=NCT00638547&rank=1 (2013).
136. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01510028?term=NCT01510028&rank=1 (2012).
137. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00920647?term=NCT00920647&rank=1 (2012).
138. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01506141?term=NCT01506141&rank=1 (2013).
139. Hirabayashi, Y., Merrill, A. H. Jr & Shayman, J. A. in Sphingolipid Biology (eds Hirabayashi, Y. et al.) 83-94 (Springer, 2006).
140. Valayannopoulos, V. & Wijburg, F. A. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford) 50 (SUPPL. 5), v49-v59 (2011).
141. Urbanelli, L. et al. Therapeutic approaches for lysosomal storage diseases: A patent update. Recent Pat. CNS Drug Discov. 8, 91-109 (2013).
142. Platt, F. M. & Jeyakumar, M. Substrate reduction therapy. Acta Paediatr. SUPPL. 97, 88-93 (2008).
143. Maegawa, G. H. et al. Substrate reduction therapy in juvenile GM2 gangliosidosis. Mol. Genet. Metab. 98, 215-224 (2009).
144. Shapiro, B. E., Pastores, G. M., Gianutsos, J., Luzy, C. & Kolodny, E. H. Miglustat in late-onset Tay-Sachs disease: A 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet. Med. 11, 425-433 (2009).
145. Young-Gqamana, B. et al. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients. PLoS ONE 8, e57631 (2013).
146. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00925301?term=NCT00925301&rank=1 (2012).
147. Lukina, E. et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood 116, 4095-4098 (2010).
148. Rountree, J. S. et al. Design, synthesis, and biological evaluation of enantiomeric -N-acetylhexosaminidase inhibitors LABNAc and DABNAc as potential agents against Tay-Sachs and Sandhoff disease. ChemMedChem 4, 378-392 (2009).
149. Tropak, M. B. et al. A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates. Glycobiology 20, 356-365 (2010).
150. Escolar, M. L., Poe, M. D., Martin, H. R. & Kurtzberg, J. A staging system for infantile Krabbe disease to predict outcome after unrelated umbilical cord blood transplantation. Pediatrics 118, e879-e889 (2006).
151. De Ru, M. H. et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: Results of a European consensus procedure. Orphanet J. Rare Dis. 6, 55 (2011).
152. Kohan, R. et al. Therapeutic approaches to the challenge of neuronal ceroid lipofuscinoses. Curr. Pharm. Biotechnol. 12, 867-883 (2011).
153. Worgall, S. et al. Neurological deterioration in late infantile neuronal ceroid lipofuscinosis. Neurology 69, 521-535 (2007).
154. Crystal, R. G. et al. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum. Gene Ther. 15, 1131-1154 (2004).
155. Sands, M. S. & Davidson, B. L. Gene therapy for lysosomal storage diseases. Mol. Ther. 13, 839-849 (2006).
156. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00976352?term=NCT00976352&rank=1 (2013).
157. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01510028?term=NCT01510028&rank=1 (2012).
158. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01474343?term=NCT01474343&rank=1 (2013).
159. Brooks, D. A., Muller, V. J. & Hopwood, J. J. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol. Med. 12, 367-373 (2006).
160. Zhang, Z. et al. Lysosomal ceroid depletion by drugs: Therapeutic implications for a hereditary neurodegenerative disease of childhood. Nat. Med. 7, 478-484 (2001).
161. Ma, X. et al. Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation. Mol. Ther. 15, 889-902 (2007).
162. Jakóbkiewicz-Banecka, J., Piotrowska, E., Narajczyk, M., Barańska, S. & Wegrzyn, G. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J. Biomed. Sci. 16, 26 (2009).
163. Xu, M. et al. λ-Tocopherol reduces lipid accumulation in niemann-Pick type C1 and Wolman cholesterol storage disorders. J. Biol. Chem. 287, 39349-39360 (2012).
164. Choudhury, A. et al. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in niemann-Pick C cells. J. Clin. Invest. 109, 1541-1550 (2002).
165. Davidson, C. D. et al. Chronic cyclodextrin treatment of murine niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS ONE 4, e6951 (2009).
166. Kirkegaard, T. et al. Hsp70 stabilizes lysosomes and reverts niemann-Pick disease-associated lysosomal pathology. Nature 463, 549-553 (2010).
167. Zhou, Q. H., Boado, R. J., Lu, J. Z., Hui, E. K. & Pardridge, W. M. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. Drug Metab. Dispos. 40, 329-335 (2012).
168. Maga, J. A. et al. Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice. J. Biol. Chem. 288, 1428-1438 (2013).
169. Montano, A. M. et al. Acidic amino acid tag enhances response to enzyme replacement in mucopolysaccharidosis type VII mice. Mol. Genet. Metab. 94, 178-189 (2008).
170. Koike, M. et al. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). Am. J. Pathol. 167, 1713-1728 (2005).
171. Repnik, U., Stoka, V., Turk, V. & Turk, B. Lysosomes and lysosomal cathepsins in cell death. Biochim. Biophys. Acta 1824, 22-33 (2012).
172. Staretz-Chacham, O., Lang, T. C., LaMarca, M. E., Krasnewich, D. & Sidransky, E. Lysosomal storage disorders in the newborn. Pediatrics 123, 1191-1207 (2009).
173. Smith, K. R. et al. Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 22, 1417-1423 (2013).
174. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01399047?term=NCT01399047&rank=1 (2013).
175. Ghosh, A., Corbett, G. T., Gonzalez, F. J. & Pahan, K. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: Implications for late infantile Batten disease therapy. J. Biol. Chem. 287, 38922-38935 (2012).
176. Miller, J. N., Chan, C. H. & Pearce, D. A. The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 22, 2723-2734 (2013).
177. Eliyahu, E. et al. Anti-TNF-alpha therapy enhances the effects of enzyme replacement therapy in rats with mucopolysaccharidosis type VI. PLoS ONE 6, e22447 (2011).
178. Coutinho, M. F., Prata, M. J. & Alves, S. Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction. Mol. Genet. Metab. 105, 542-550 (2012).
179. Koeberl, D. D. et al. Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle. Mol. Genet. Metab. 103, 107-112 (2011).
180. Li, S. et al. Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease. FASEB J. 27, 34-44 (2013).
181. Messinger, Y. H. et al. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet. Med. 14, 135-142 (2012).
182. Abbott, M. A. et al. Atypical immunologic response in a patient with CRIM-negative Pompe disease. Mol. Genet. Metab. 104, 583-586 (2011).
183. Jmoudiak, M. & Futerman, A. H. Gaucher disease: Pathological mechanisms and modern management. Br. J. Haematol. 129, 178-188 (2005).
184. Lake, B. D., Young, E. P. & Winchester, B. G. Prenatal diagnosis of lysosomal storage diseases. Brain Pathol. 8, 133-149 (1998).
185. Summary of Gaucher Disease Patient Prioritization For Treatment Recommendations From The Meeting Of Gaucher Treatment Experts, September 9th, 2009, Chicago, IL, USA. Gaucher Disease Organization [online] http://www.gaucherdisease.org/shire-patient-prioritization.pdf (2009).
186. Brady, R. O. Enzyme replacement for lysosomal diseases. Annu. Rev. Med. 57, 283-296 (2006).
187. Bailey, L. An overview of enzyme replacement therapy for lysosomal storage diseases. Online J. Issues Nurs. 13, manuscript 3 (2008).
188. Guo, W. X., Mao, C., Obeid, L. M. & Boustany, R. M. A disrupted homologue of the human CLN3 or juvenile neuronal ceroid lipofuscinosis gene in Saccharomyces cerevisiae: A model to study Batten disease. Cell. Mol. Neurobiol. 19, 671-680 (1999).
189. Chattopadhyay, S., Muzaffar, N. E., Sherman, F. & Pearce, D. A. The yeast model for batten disease: Mutations in btn1, btn2, and hsp30 alter pH homeostasis. J. Bacteriol. 182, 6418-6423 (2000).
190. Boustany, R. M., Shareef, I. & El-Haddad, S. in Emery and Rimoin?s Principles and Practice of Medical Genetics Ch. 109 (Elsevier, 2013).
191. Auffray, C. et al. Genome Medicine: Past, present and future. Genome Med. 3, 6 (2011).
192. Khoury, M. J. Public health genomics: 15 years on. Centers for Disease Control and Prevention [online], http://blogs.cdc.gov/genomics/2013/01/03/ public-health-genomics-15-years-on/(2013).
193. Benitez, B. A. et al. Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. PLoS ONE 6, e26741 (2011).
194. Smith, K. R. et al. Strikingly different clinicopathological phenotypes determined by progranulin-mutation dosage Am. J. Hum. Genet. 90, 1102-1107 (2012).
195. Staropoli, J. F. et al. A homozygous mutation in KCTD7 links neuronal ceroid lipofuscinosis to the ubiquitin-proteasome system. Am. J. Hum. Genet. 91, 202-208 (2012).